New study aims to reduce DKA risk for type 1 diabetes patients using SGLT2 inhibitors
NCT ID NCT07421518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special education plan using continuous ketone monitoring can lower the risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes who also take SGLT2 inhibitors, a drug class that raises DKA risk. About 75 adults with type 1 diabetes will be enrolled and followed to compare the special plan to standard education. The goal is to improve safety while using these medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Translational Research Institute
Orlando, Florida, 32804, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?